In the PARADIGM-HF study, angiotensin receptor/neprilysin inhibitor sacubitril/valsartan was shown to be superior to enalapril in reducing the risk of death and hospitalization for HF [1]. The gene discussed is MME; the disease is hydrops fetalis.